Tag Archives: antiviral

Drug companies ramp up development of COVID-19 prevention and treatment products

Bara Vaida

About Bara Vaida

Bara Vaida (@barav) is AHCJ's core topic leader on infectious diseases. An independent journalist, she has written extensively about health policy and infectious diseases. Her work has appeared in outlets that include the National Journal, Agence France-Presse, Bloomberg News, McClatchy News Service, MSNBC, NPR, Politico and The Washington Post.

COVID-19

Photo: NIAID-RML via FlickrAn electron microscope image of SARS-CoV-2 — also known as 2019-nCoV — which is the virus that causes COVID-19.

With the number of COVID-19 cases expanding exponentially, the story about the potential for treatments and vaccines remains a top priority. So does the story of drug pricing.

At a March 5 media briefing on Capitol Hill, biopharmaceutical company executives updated legislaters on potential medical countermeasures for stopping the SARS-CoV-2 virus, which causes the disease COVID-19.

One of the most promising drugs is remdesivir, an antiviral under development by biotech company Gilead Sciences. Continue reading